Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: Synthesis and evaluation as anticancer conjugates

Water soluble polymer anticancer conjugates can improve the pharmacokinetics of covalently bound drugs by limiting cellular uptake to the endocytic route, thus prolonging plasma circulation time and consequently facilitating tumor targeting by the enhanced permeability and. retention (EPR) effect. Many of the first generation antitumor polymer conjugates used nonbiodegradable polymeric carriers which limits the molecular weight that can be safely used to < 40 000 g/mol. The aim of this ambitious study was to synthesize and evaluate a novel, prototype biodegradable polymeric system based on high molecular weight, water-soluble functionalized polyesters. The main polymeric platform was prepared from bis(4-hydroxy)butyl maleate (DBM) and poly(ethylene glycol) (PEG(4000)) blocks to give the polymer DBM2-PEG(4000) containing biodegradable carbonate bonds and having a M-w of 100 000- 190 000 g/mol; M-n of 37 000-53 000 g/mol, and M-w/M-n of 3.0-3.7. Using thioether linkages, this polymer was then grafted with HS-PEG(3000)-Gly-Phe-Lue-Gly doxorubicin (HS-PEG(3000)-GFLG-Dox) pendant side chains (similar to 30 per DBM2-PEG chain). The final construct, DBM2-PEG(4000)-S-PEG(3000)-GFLG-Dox had a total Dox content of 3-4 wt % and a free Dox content of <= 0.7% total Dox. During incubation with isolated lysosomal enzymes, the rate of Dox release from the polymer backbone was relatively slow (< 5% release over 5 h) compared to that seen for PEG(5000-)GFLG-Dox alone (> 20% over 5 h). The in vitro cytotoxicity was assessed using 1316F10 murine melanoma (MTT assay). DBM2-PEG(4000)-S-PEG(3000)-GFLG-Dox was 10-20-fold less toxic than free Dox. In vivo antitumor activity of the DBM2-PEG(4000)-S-PEG(3000)-GFLG-Dox conjugates was assessed using a subcutaneous (s.c.) B16F10 murine melanoma model, and an intraperitoneal (i.p.) L1210 leukaemia model. The increased toxicity (attributed to poor solubility) and low antitumor activity of DBM2-PEG(4000)-S-PEG(3000)-GFLG-Dox conjugates compared to PEG(5000)-GFLG-Dox and HPMA copolymer-Dox conjugates was attributed to the slow rate of Dox release. The DBM2-PEG(4000)-S-PEG(3000)-GFLG-Dox conjugates were considered unfavorable as candidates for further development. However, the successful scale-up synthesis of DBM2-PEG(4000)-SPEG(3000) constructs suggest that they are worthy of further investigation as carriers for controlled release and targeting of less hydrophobic agents.